Johnson & Johnson Shares Rise as UBS Raises Price Target to $320
Johnson & Johnson shares rose about 1.2% to $274.40 after UBS lifted its price target from $280 to $320 and kept a Buy rating. UBS cited faster growth and value within J&J’s pharmaceutical pipeline. The company’s second-quarter sales climbed 6.6% to $25.3 billion, with management raising its 2026 sales midpoint and adjusted earnings outlook, though valuation remains stretched.